IMPORTANCE Some proponents of telemedicine screening for retinopathy of prematurity (ROP) believe that a screening system based on the characteristics of posterior pole vessels is sufficient for identifying infants needing treatment.
R etinopathy of prematurity (ROP) requires proper screening and treatment to reduce the risk for progression to retinal detachment and blindness. Because of the sequential progression of ROP, at-risk infants require longitudinal evaluation. Current published screening guidelines 1 suggest a follow-up examination schedule based on retinal findings noted at each examination, based on the international classification system. 2 As the use of digital photographs for ROP screening expands, establishing an appropriate imaging interval to ensure treatable ROP is not missed will be important. Although some proponents of telemedicine screening for ROP believe that the periphery must be captured in acquired images, 3, 4 others propose that a screening system based solely on vessel characteristics in the posterior pole is sufficient. [5] [6] [7] We sought to determine whether the vessel characteristics seen in the posterior pole are sufficient for identifying infants who need treatment for ROP and a maximal imaging interval to ensure treatmentrequiring ROP is not missed. Thus, the purpose of this study was to evaluate the vascular characteristics present at the time that an infant was determined to need treatment for ROP and the number of days from the last examination when the vessels were noted to be normal bilaterally until a decision was made to treat.
Methods
All infants treated for ROP who underwent longitudinal examination in the neonatal intensive care unit (NICU) at Duke University Hospital, Durham, North Carolina, from June 22, 2013, through May 2, 2017, were included in this study. This retrospective study was approved by the institutional review board of Duke University Health System and conformed to the requirements of the US Health Insurance Portability and Privacy Act. The institutional review board permitted waiving of informed consent. In our NICU, infants underwent screening using indirect ophthalmoscopy by one of us (D.K.W. or S.F.F.) each with more than 20 years of experience screening for ROP. Screening was performed according to current ROP screening guidelines in the United States, 1 and treatment was performed when infants reached criteria for type 1 ROP, defined as zone I ROP with plus disease, zone I ROP with stage 3 disease, or zone II ROP with stage 2 or 3 and plus disease. 8 We calculated the number of days from the last examination when the vessels in the posterior poles of both eyes were noted to be normal until a decision was made to treat for ROP in 1 or both eyes.
Results
During the study period, 55 infants (30 male and 25 female) were treated for ROP after longitudinal examination in our NICU. None of the infants had abnormal posterior pole vessels on their first clinical examination. Of the 55 infants included, mean birthweight was 733 g (range, 420-1060 g); mean gestational age, 25.1 weeks (range, 22.9-27.7 weeks); and mean postmenstrual age (PMA) at the time a decision was made to treat, 36.7 weeks (range, 31.4-43.0 weeks). All infants met criteria for type 1 ROP when a decision was made to treat ( Table 1) . Of the 55 infants treated for ROP, 51 (93%) had plus disease. Four infants (7%) had zone I, stage 3 ROP without plus disease (3 with preplus disease and 1 with neither preplus nor plus disease).
The time from the last examination when the vessels were noted to be normal bilaterally until a decision was made to treat ROP ranged from 0 to 49 days ( Table 2 ). For 13 infants (24%), the interval was less than 14 days. Among these infants, 10 had ROP in zone I and 3 had ROP in zone II. For all but 1 infant (98%), the interval was at least 7 days.
The infant with neither preplus nor plus disease in either eye when the examiner decided to treat for type 1 ROP had a birthweight of 730 g and gestational age of 24.4 weeks. On the first ROP examination at a PMA of 30.1 weeks, the infant had immature vessels in zone I and normal posterior pole vessels bilaterally. The infant was examined weekly and always had ROP in zone I without preplus or plus disease. In both eyes, stage 1 was noted at a PMA of 31.1 weeks, stage 2 at a PMA of 32.1 weeks, and stage 3 at a PMA of 34.1 weeks, at which time a decision was made to treat the infant for ROP because the disease had reached criteria for type 1 ROP (6 clock hours of stage 3 ROP in zone I bilaterally). On the day that the decision was made to treat, the examiner noted that both eyes had no vascular dilation or tortuosity but that the number and branching of vessels was prominent bilaterally.
Discussion
We found that on the clinical examination when an infant was determined to need treatment for ROP, most infants had preplus or plus disease, and at least 7 days had passed from when they were last noted to have normal vessels in both eyes. The exception was 1 infant with neither preplus nor plus disease at the time that a decision was made to treat. This infant had ROP in zone I and a prominent number and branching of vessels bilaterally. Although 1 study found that "normal posterior pole vessels are a reliable marker for the absence of stage 3 ROP" 9(p82) among 132 consecutive patients screened for ROP, we suspect the single exception that we found in the present study may be attributable to the low gestational age (24.4 weeks) (the range of gestational ages of infants in the study conducted >25 years ago was not published) and/or the rarity of this clinical scenario. Both examiners, each with more than 20 years of ROP screening experience, have never seen a similar case. Ophthalmologists screening for ROP should be aware that although rare, zone I, stage 3 ROP is possible with neither preplus nor plus disease.
As the use of digital photographs for ROP screening increases, establishing the minimum field of view and imaging interval needed to ensure that infants are appropriately screened and that treatment-requiring disease is not missed will be important. Although narrow-field imaging devices can be used to screen for ROP with high sensitivity, [5] [6] [7] we suspect that if the field of view includes all of zone I, no treatable ROP will be missed with images of acceptable quality. In the single case in which neither preplus nor plus disease was present when a decision was made to treat in the present study, narrow-field imaging including zone I likely would have demonstrated the stage 3 ROP and/or the abnormal vessel branching seen in zone I to prompt referral for ophthalmic examination. Our findings also showed that imaging with a narrow-field device at 2-week intervals could miss as many as 24% of infants needing treatment, whereas imaging at intervals of 7 days should identify infants needing treatment.
Limitations
One limitation of this study is that we did not have photographic documentation of the single infant without preplus or plus disease. Thus, whether any vascular abnormalities (ie, slight vascular tortuosity or dilation that did not qualify as preplus disease) were present cannot be confirmed.
Conclusions
Our results suggest that narrow-field imaging for ROP screening should include all of zone I to identify rare treatmentrequiring ROP with normal posterior pole vessels. If confirmed, with sufficient image quality, weekly photographic screening of zone I should capture changes indicative of impending ROP requiring treatment. Abbreviation: ROP, retinopathy of prematurity. a For asymmetric disease, the first eye treated or the eye with the lower zone with worst posterior pole disease was selected for classification.
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